ORIGINAL RESEARCH article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1546044
Oral microbiome components predict response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Provisionally accepted
- Department of General Surgery (Breast Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The oral microbiome has emerged as a critical biomarker and regulator in cancer development and treatment response, garnering increasing attention from researchers. However, its specific role in breast cancer, particularly in triple-negative breast cancer (TNBC), remains poorly understood. The influence of the oral microbiome on chemotherapy sensitivity in TNBC, along with the underlying molecular mechanisms, remains unclear. Further investigation is needed to assess its potential as a biomarker for predicting chemotherapy sensitivity in this patient population. In the present study, significant differences in the composition of the oral microbiome were observed among patients with varying chemotherapy sensitivities for TNBC patients. Additionally, notable changes in the oral microbiome were noted after chemotherapy in patients with favorable responses to treatment. Our analysis revealed that chemotherapy-sensitive patients had higher levels of Lactobacillus and Neisseria species, alongside lower levels of Clostridium species. Post-chemotherapy, patients with positive responses demonstrated an increase in Clostridium and Microbacterium species, along with a decrease in Streptococcus and Neisseria. In contrast, no significant changes were observed in the microbiota of patients with poor chemotherapy responses. A classifier based on these microbial biomarkers yielded an area under the curve (AUC) value of 77.3% (95% CI: 60.5%-94.2%), supporting the potential of the oral microbiome as a predictive tool for chemotherapy sensitivity in TNBC. Given its simplicity, non-invasiveness, and repeatability, the oral microbiome holds promise as a valuable biomarker for predicting neoadjuvant chemotherapy sensitivity in TNBC patients.
Keywords: oral microbiome, Triple-negative breast cancer, neoadjuvant chemotherapy sensitivity, response-prediction model, biomarker
Received: 16 Dec 2024; Accepted: 03 Jul 2025.
Copyright: © 2025 Fu, Huang, Li, Chen, Wu, Yang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiaoyan Fu, Department of General Surgery (Breast Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
Haiyan Li, Department of General Surgery (Breast Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.